Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor

a non-proteolytically activated thrombin and cartilage growth technology, which is applied in the direction of prosthesis, peptide/protein ingredients, peptide sources, etc., can solve the problems of cartilage self-repair after injury, disease, surgery, etc., and the cost of cartilage repair from acute joint injury (meniscal lesions, patellar surface damage and chondromalacia) exceeds $1 billion annually. , to stimulate proliferation and matrix production

Inactive Publication Date: 2005-08-18
ORTHOLOGIC
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0004] It has now been found that chondrocytes isolated from articular cartilage respond to compounds which activate the non-proteolytic thrombin cell surface receptor (hereinafter “NPAR”). For example, chondrocytes express approximately 233,000 thrombin binding sites per cell with apparent affinities of approximately 0.1 nM (3000 sites) and 27 nM (230,000 sites) (Example 1). In addition, the compound TP508, an agonist of the non-proteolytic thrombin receptor, stimulates proliferation of bovine chondrocytes in culture in the presence of thrombin as a co-mitogen (Example 2A) and stimulates by itself the proliferation of rat chondrocytes cultured in three dimensional matrix culture (Example 3A). This same TP508 compound also stimulates...

Problems solved by technology

The inability of cartilage to self-repair after injury, disease, or surgery is a major limiting factor in rehabilitation of degrading joint surfaces and injury to meni...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor

Examples

Experimental program
Comparison scheme
Effect test

example 1

Thrombin Binding to Rat Chondrocytes

[0046] Primary cultures of rat articular chondrocytes were isolated and prepared for in vitro analysis using established methods (see Kuettner, K E., et. al., J. Cell Biology 93: 743-750, 1982). Briefly, cartilage pieces were dissected from the shoulder of rats and the pieces were digested with trypsin for one hour and with collagenase for three hours in tissue culture medium (DMEM) at 37 C with stirring. The cells were plated in flasks at high density (50,000 cells / cm sq.) and were culture in DMEM containing antibiotics an ascorbic acid at 37° C. in an atmosphere of 5% CO2.

[0047] The specific binding of 125I thrombin to chondrocytes was carried out using established thrombin receptor binding assays as disclosed in U.S. Pat. No. 5,352,664 and Carney, D. H. and Cunningham, D. D., Cell 15:1341-1349 (1978). Briefly, highly purified human thrombin was iodinated and added to cultures of chondrocytes with or without unlabeled thrombin to correct for n...

example 2a

NPAR Agonist Stimulation of Bovine Chondrocyte Proliferation

[0049] Primary cultures of bovine chondrocytes were prepared using the procedure described for rat chondrocytes in Example 1. The cultures were subcultured into 24 well plastic dishes at a low density and placed in 1% serum. Addition of the NPAR agonist TP508 to these cultures at concentrations of 1.0 or 10 μg / ml by itself did not stimulate cell proliferation. In contrast, addition of these concentrations of TP508 together with a small amount of thrombin co-mitogen, resulted in a small, but significant (p<0.05) increase in cell number relative to that seen in thrombin alone after three days in culture.

example 2b

NPAR Agonist Stimulation of Bovine Chondrocyte Proteoglycan Synthesis

[0050] To determine the effect of NPAR agonists on proteoglycan synthesis, bovine chondrocytes were seeded into 96 well plates at a density of 2×105 cells per well and cultured in DMEM with 10% fetal calf serum. After establishment of these multi-layer cultures, the medium was replaced daily with DMEM containing 1% serum with indicated concentrations of TP508 from 1 to 100 μg per ml (Table 1). After 6 days in culture with daily changes of culture medium with or without TP508, 35S sulfate was added to the medium and incubation continued for an additonal 24 hours. As shown in Table 1, treatment with high concentrations of TP508 (100 μg per ml) increased 35S sulfate incorporation relative to untreated cells by more than 10-fold.

TABLE 1Effect of the NPAR agonist TP508 on 35S sulfate incorporation inbovine chondrocyte cultures.Mean CPMTreatment1% SerumStd. Dev of MeanControl49753552TP508 (1 μg / ml)47012692TP508 (10 μg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Biocompatibilityaaaaaaaaaa
Login to view more

Abstract

Disclosed is a method of stimulating cartilage growth, repair or regeneration at a site in a subject in need of such growth, repair or regeneration. The method comprises the step of administering a therapeutically effective amount of an agonist of the non-proteolytically activated thrombin receptor to the site. Also disclosed is a method of stimulating the proliferation and expansion of chrondrocytes in vitro. The method comprises culturing chrondrocytes in the presence of a stimulating amount of an NPAR agonist.

Description

RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 10 / 050,688, filed Jan. 16, 2002, which is a continuation-in-part of U.S. application Ser. No. 09 / 909,348, filed Jul. 19, 2001, which claims the benefit of U.S. Provisional Application No. 60 / 219,800, filed Jul. 20, 2000. The entire teachings of the above applications are incorporated herein by reference.GOVERNMENT SUPPORT [0002] The invention was supported, in whole or in part, by grant 1 R43 AR46343-01 from the National Institutes of Health / National Institute of Arthritis and Muscoskeletal and Skin Diseases. The Government has certain rights in the invention.BACKGROUND OF THE INVENTION [0003] Unlike most tissues, cartilage does not self-repair following injury. Cartilage is an avascular tissue made up largely of cartilage specific cells, the chondrocytes, special types of collagen, and proteoglycans. The inability of cartilage to self-repair after injury, disease, or surgery is a major limit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/32A61K38/00A61K38/17C12N9/74A61K38/46A61K38/48A61K45/00A61K47/34A61L27/00A61L27/18A61L27/22A61L27/54A61P17/02A61P19/00A61P19/02A61P19/08A61P43/00
CPCA61K38/4833A61L27/18A61L27/227A61L27/54A61L2300/25A61K38/465A61L2300/40A61L2300/412A61L2430/06A61L2300/252C08L67/04A61P17/02A61P19/00A61P19/02A61P19/08A61P43/00
Inventor CARNEY, DARRELLCROWTHER, ROGERSTIERNBERG, JANETBERGMANN, JOHN
Owner ORTHOLOGIC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products